Danaher Corporation
NYQ: DHRLive Quote
📈 ZcoreAI Score
Our AI model analyzes Danaher Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get DHR Z-Score →About Danaher Corporation
Healthcare
Diagnostics & Research
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
📊 Fundamental Analysis
Danaher Corporation demonstrates a healthy profit margin of 14.7%.
The company recently reported 4.6% revenue growth, which is modest compared to its industry peers.
Return on Equity (ROE) is 7.1%, which suggests room for improvement in capital utilization.
At a current price of $189.61, DHR currently trades near the bottom of its 52-week range (15%), indicating potential value or weakness (Range: $180.03 - $242.80).
💰 Valuation Insight
DHR trades at a 51.1% premium to the sector average PE of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
⚠️
Profit Margin
Moderate
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$134.19B
Trailing P/E
37.77
Forward P/E
20.82
Beta (5Y)
0.99
52W High
$242.80
52W Low
$180.03
Avg Volume
4.17M
Day High
Day Low